Nonsteroidal anti-inflammatory drugs targeting PTGS2 have been shown to inhibit the proliferation of cultured hepatocellular cancer cells by inducing cell-cycle arrest [53]. Here, PTGS2 is linked to hepatocellular carcinoma.